Voices
Diego Díaz-García
Diego A. Díaz-García/X

Diego Díaz-García: Rituximab as Adjunctive Therapy in FSGS

Diego Díaz-García, Medical Oncologist, CEO, and Founder of CánCare – Advanced Oncology Specialty, shared a post on X:

“Rituximab as Adjunctive Therapy in FSGS

Response rates: 3, 6, and 12 months: 57, 71, and 74%

12 month RTX response was positively associated:

-↓ Proteinuria: OR= 0.49, P = 0.043

-Steroid dependency: OR = 20.59, P = 0.002

Sustained remission in 1year responders: 69.4%.”

Title: Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis

Authors: Osama Nady Mohamed, Marwa Ibrahim Mohamed, Shereen Mohammed Elsaghir, Shimaa Abdelrazek, Aml Azzam, Tarek Mahmoud Senosy Mohamed, Hassan M.H. Mohammed, Rasha Yousef, Ayman Ahmed Abd Rabou, Reem Y. Abdelazeem Elgarhy, Alaa Khalifa Mohamed Mahdy, Mohamed Ahmed Abdelsamie, Manar M. Sayed, Eman Fathi, Nermeen Dahi Mohammed Toni, Rabeh Khairy Saleh, Basma Fathy

Read the Full Article.

Diego Díaz-García

More posts featuring Diego A. Díaz-García.

Alaa Khalifa Mohamed Mahdy Aml Azzam Ayman Ahmed Abd Rabou Basma Fathy Diego A. Díaz García Diego Díaz García Eman Fathi Hassan M.H. Mohammed Manar M. Sayed Marwa Ibrahim Mohamed Mohamed Ahmed Abdelsamie Nermeen Dahi Mohammed Toni Osama Nady Mohamed Rabeh Khairy Saleh Rasha Yousef Reem Y. Abdelazeem Elgarhy Shereen Mohammed Elsaghir Shimaa Abdelrazek Tarek Mahmoud Senosy Mohamed